News
Jincheng Pharmaceutical Glutathione API GMP Certificate

Jincheng Pharmaceutical Glutathione API GMP Certificate

2014-11-20

Securities Times Network, December 10-Jincheng Pharmaceutical (300233 shares, market quotation, information, main trading) announced on the evening of the 10th that after on-site inspection and examination and approval, Shandong Jincheng Biopharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, recently passed the new version of GMP certification in the 200-ton/year glutathione API workshop and obtained the "Drug GMP Certificate".

View Details
Peking University Medicine Declares Class 3 Tumor Raw Material Drugs No Domestic Enterprise Produces

Peking University Medicine Declares Class 3 Tumor Raw Material Drugs No Domestic Enterprise Produces

2014-11-20

The website of the State Administration of Food and Drug Administration (CFDA) shows that Peking University Medicine (quotation, consultation)(000788.SZ) has accepted the application of 3 types of clinical antitumor chemical drug gefitinib. At present, only the original research tablets are on sale in China, and no domestic enterprises produce gefitinib and related preparations.

View Details
Peking University Medicine Declares Class 3 Tumor Raw Material Drugs No Domestic Enterprise Produces

Peking University Medicine Declares Class 3 Tumor Raw Material Drugs No Domestic Enterprise Produces

2014-11-20

The website of the State Administration of Food and Drug Administration (CFDA) shows that Peking University Medicine (quotation, consultation)(000788.SZ) has accepted the application of 3 types of clinical antitumor chemical drug gefitinib. At present, only the original research tablets are on sale in China, and no domestic enterprises produce gefitinib and related preparations.

View Details
Zhu Baoguo Medical Mengqi Oral Liquid Transformation of Raw Material Drug Integration Road Rugged

Zhu Baoguo Medical Mengqi Oral Liquid Transformation of Raw Material Drug Integration Road Rugged

2014-11-20

With the announcement of the termination of the planning of major matters and the resumption of trading by the Health Yuan and Lizhu Group, the asset integration path of Zhu Baoguo's pharmaceutical empire, which had been widely rumored in the industry, emerged: the proposed initiation of the integration of fermentation API transactions between the two companies.

View Details
< 1 >